Condition: Hyperlipidemia · Sponsor: Shandong Suncadia Medicine Co., Ltd.
The purpose of the study is to explore the reasonable dosage of HRS-1301 in participants with dyslipidemia. The efficacy and safety of HRS-1301 will be evaluated after 12-weeks treatment.
This description comes directly from the study's public registry record.
Miaomiao Shi · 18036617171 · Miaomiao.shi@hengrui.com
Always discuss trial participation with your own doctor first.
| The 2nd Affiliated Hospital of Harbin | Harbin, Heilongjiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07229937